Dogwood Therapeutics Financials - Benzinga

Dogwood Therapeutics Inc

DWTXNASDAQ

Trade with Public

Trade with Public

$2.68

0.124.69%

At close: Aug 24, 5:00 PM EST

$2.62

0.062.34%

Pre-Market: 4:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Dogwood Therapeutics Financials

Dogwood Therapeutics (DWTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate

Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.14) by 142.86 percent. This is a 82.91 percent increase over losses of $(1.99) per

Benzinga Newsdesk

PRO
Dogwood Therapeutics Q1 EPS $(0.15), Inline

Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 98.22 percent increase over losses of $(8.45) per share from the same period last

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Dogwood Therapeutics Q4 EPS $(0.26) Beats $(1.17) Estimate

Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.17) by 77.83 percent. This is a 95.87 percent increase over losses of $(6.29) per share

Benzinga Newsdesk

PRO
Dogwood Therapeutics Q3 EPS $(8.20) Misses $(1.58) Estimate

Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(8.20) per share which missed the analyst consensus estimate of $(1.58) by 418 percent. This is a 300 percent decrease over losses of $(2.05) per share

Benzinga Newsdesk

PRO
Dogwood Therapeutics Q2 EPS $(1.99) Misses $(1.90) Estimate

Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(1.90) by 4.74 percent. This is a 73.04 percent decrease over losses of $(1.15) per share

Benzinga Newsdesk